159 related articles for article (PubMed ID: 22588604)
1. Compartment-specific gene regulation of the CAR inducer efavirenz in vivo.
Meyer zu Schwabedissen HE; Oswald S; Bresser C; Nassif A; Modess C; Desta Z; Ogburn ET; Marinova M; Lütjohann D; Spielhagen C; Nauck M; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2012 Jul; 92(1):103-11. PubMed ID: 22588604
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
Wyen C; Hendra H; Siccardi M; Platten M; Jaeger H; Harrer T; Esser S; Bogner JR; Brockmeyer NH; Bieniek B; Rockstroh J; Hoffmann C; Stoehr A; Michalik C; Dlugay V; Jetter A; Knechten H; Klinker H; Skaletz-Rorowski A; Fätkenheuer G; Egan D; Back DJ; Owen A;
J Antimicrob Chemother; 2011 Sep; 66(9):2092-8. PubMed ID: 21715435
[TBL] [Abstract][Full Text] [Related]
3. Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor.
Cortes CP; Siccardi M; Chaikan A; Owen A; Zhang G; la Porte CJ
Ther Drug Monit; 2013 Feb; 35(1):78-83. PubMed ID: 23172109
[TBL] [Abstract][Full Text] [Related]
4. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.
Ma Q; Forrest A; Rosenkranz SL; Para MF; Yarasheski KE; Reichman RC; Morse GD;
Biopharm Drug Dispos; 2008 Mar; 29(2):91-101. PubMed ID: 18041735
[TBL] [Abstract][Full Text] [Related]
6. CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.
Maimbo M; Kiyotani K; Mushiroda T; Masimirembwa C; Nakamura Y
Eur J Clin Pharmacol; 2012 Mar; 68(3):267-71. PubMed ID: 21901344
[TBL] [Abstract][Full Text] [Related]
7. High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe.
Nyakutira C; Röshammar D; Chigutsa E; Chonzi P; Ashton M; Nhachi C; Masimirembwa C
Eur J Clin Pharmacol; 2008 Apr; 64(4):357-65. PubMed ID: 18057928
[TBL] [Abstract][Full Text] [Related]
8. Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.
Oswald S; Meyer zu Schwabedissen HE; Nassif A; Modess C; Desta Z; Ogburn ET; Mostertz J; Keiser M; Jia J; Hubeny A; Ulrich A; Runge D; Marinova M; Lütjohann D; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2012 Mar; 91(3):506-13. PubMed ID: 22297387
[TBL] [Abstract][Full Text] [Related]
9. Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index.
Jiang F; Desta Z; Shon JH; Yeo CW; Kim HS; Liu KH; Bae SK; Lee SS; Flockhart DA; Shin JG
Br J Clin Pharmacol; 2013 Jan; 75(1):244-53. PubMed ID: 22554354
[TBL] [Abstract][Full Text] [Related]
10. In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.
Rekić D; Röshammar D; Mukonzo J; Ashton M
Br J Clin Pharmacol; 2011 Apr; 71(4):536-43. PubMed ID: 21395646
[TBL] [Abstract][Full Text] [Related]
11. A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.
Gandhi M; Greenblatt RM; Bacchetti P; Jin C; Huang Y; Anastos K; Cohen M; Dehovitz JA; Sharp GB; Gange SJ; Liu C; Hanson SC; Aouizerat B;
J Infect Dis; 2012 Nov; 206(9):1453-61. PubMed ID: 22927450
[TBL] [Abstract][Full Text] [Related]
12. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans.
Mouly S; Lown KS; Kornhauser D; Joseph JL; Fiske WD; Benedek IH; Watkins PB
Clin Pharmacol Ther; 2002 Jul; 72(1):1-9. PubMed ID: 12151999
[TBL] [Abstract][Full Text] [Related]
13. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
[TBL] [Abstract][Full Text] [Related]
14. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.
Ogburn ET; Jones DR; Masters AR; Xu C; Guo Y; Desta Z
Drug Metab Dispos; 2010 Jul; 38(7):1218-29. PubMed ID: 20335270
[TBL] [Abstract][Full Text] [Related]
15. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.
Cabrera SE; Santos D; Valverde MP; Domínguez-Gil A; González F; Luna G; García MJ
Antimicrob Agents Chemother; 2009 Jul; 53(7):2791-8. PubMed ID: 19433561
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
Holzinger ER; Grady B; Ritchie MD; Ribaudo HJ; Acosta EP; Morse GD; Gulick RM; Robbins GK; Clifford DB; Daar ES; McLaren P; Haas DW
Pharmacogenet Genomics; 2012 Dec; 22(12):858-67. PubMed ID: 23080225
[TBL] [Abstract][Full Text] [Related]
17. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.
Carr DF; la Porte CJ; Pirmohamed M; Owen A; Cortes CP
J Antimicrob Chemother; 2010 Sep; 65(9):1889-93. PubMed ID: 20639527
[TBL] [Abstract][Full Text] [Related]
18. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.
Ramachandran G; Hemanth Kumar AK; Rajasekaran S; Kumar P; Ramesh K; Anitha S; Narendran G; Menon P; Gomathi C; Swaminathan S
Antimicrob Agents Chemother; 2009 Mar; 53(3):863-8. PubMed ID: 19124658
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children.
Viljoen M; Karlsson MO; Meyers TM; Gous H; Dandara C; Rheeders M
Eur J Clin Pharmacol; 2012 Apr; 68(4):339-47. PubMed ID: 22057858
[TBL] [Abstract][Full Text] [Related]
20. Coordinated roles of pregnane X receptor and constitutive androstane receptor in autoinduction of voriconazole metabolism in mice.
Ohbuchi M; Yoshinari K; Kaneko H; Matsumoto S; Inoue A; Kawamura A; Usui T; Yamazoe Y
Antimicrob Agents Chemother; 2013 Mar; 57(3):1332-8. PubMed ID: 23274663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
